Topic: tardive dyskinesia
In the tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says.
With Teva slated to cut $3 billion in costs, every area of the company will feel the impact of its restructuring plan. Well, almost.
A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.
Downtrodden Teva Wednesday got some good news—and Neurocrine got some company.
Neurocrine’s Ingrezza, fresh off its first FDA approval and aiming for another, just hit a major roadblock.
Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.
The tardive dyskinesia market race is officially on—and it’s Neurocrine that has the go-ahead to kick things off.
Under pressure in generics, Teva could use some help from its specialty department, and the newly approved Huntington’s chorea med Austedo could bring just that.